In Type 1 ROP (requiring treatment), laser photocoagulation is applied to:

• A The posterior pole and all vascularized retina up to the equator
• B The ridge and neovascular tissue directly
• C The entire retinal surface including the macula
• D The avascular peripheral retina anterior to the ridge ✓

Explanation

Laser photocoagulation for Type 1 ROP (Zone I any stage with plus disease, Zone I Stage 3 without plus, or Zone II Stage 2–3 with plus disease) targets the avascular retina anterior to the fibrovascular ridge. This destroys the peripheral ischemic retina that produces angiogenic factors (VEGF), thereby reducing the stimulus for neovascularization. The macula and posterior vascularized retina are avoided. Intravitreal anti-VEGF (bevacizumab/ranibizumab) is now an alternative, especially for Zone I disease.

Reference: Khurana Comprehensive Ophthalmology, 7th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.